Impact of nafarelin and leuprolide for endometriosis on quality of life and subjective clinical measures.
article
OA: closed
CC0
⤵ 8 in-corpus citations
AI-generated summary
Nafarelin treatment for endometriosis showed greater quality of life improvement in severe symptom patients and fewer hot flashes compared to leuprolide.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To examine the impact of treating endometriosis with nafarelin or leuprolide acetate depot on patient quality of life (QOL) and subjective clinical measures. STUDY DESIGN: A randomized, multicenter study was conducted on 192 women with endometriosis. Patients received nafarelin or leuprolide for six months and were followed for up to six months after treatment. QOL was defined by seven items, including symptom severity, daily activities, pain medication use and need for bed rest. RESULTS: No significant differences were found at baseline between treatments for patients with mild, moderate or no endometriosis symptoms. Those with severe symptoms of endometriosis at baseline and taking nafarelin had a significantly greater improvement in QOL at the last posttreatment visit than those receiving leuprolide (P < .01). Nafarelin was associated with significantly fewer days with moderate or severe hot flashes than leuprolide during treatment (P < .05) and with significantly fewer moderate or severe hypoestrogenic symptoms overall at three months of treatment (P < .05). Additionally, poorer QOL was significantly associated with hypoestrogenic and endometriosis symptoms. CONCLUSION: Treatment of endometriosis with nafarelin was associated with fewer days of moderate or severe hot flashes as compared to leuprolide and with greater improvement in QOL after treatment in patients with severe symptoms at baseline.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (8)
- A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action 2024
- Place et modalités du traitement médical de l’endométriose 2022
- An investigation of the surgical treatment of endometriosis 2010
- Health-related quality of life burden of women with endometriosis: a literature review 2006
- Quality of life instruments in studies of chronic pelvic pain: a systematic review 2004
- Laparoscopic excision of endometriosis: A randomized, placebo-controlled trial 2004
- The management of advanced‐stage endometriosis in the treatment of infertility 2001
- Acute exacerbation of chronic maxillary sinusitis during therapy with nafarelin nasal spray 2001
SciLite annotations
chemicals 13
nafarelin
leuprolide
nafarelin
leuprolide
acetate
nafarelin
leuprolide
nafarelin
leuprolide
nafarelin
leuprolide
nafarelin
leuprolide
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:13:41.710148+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0
· commercial use OK